Hormone shots plus vaccine may supercharge immune attack on prostate cancer
NCT ID NCT06100705
First seen Nov 06, 2025 · Last updated May 05, 2026 · Updated 25 times
Summary
This study tests whether adding bipolar androgen therapy (short-term hormone treatment) to the standard Sipuleucel-T vaccine can strengthen the immune system's response against prostate cancer cells. About 26 men with metastatic castration-resistant prostate cancer will receive both treatments. The goal is to see if the combination boosts immune activity more than the vaccine alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.